Tgf-β1 transcriptionally promotes 90K expression: possible implications for cancer progression.
Journal
Cell death discovery
ISSN: 2058-7716
Titre abrégé: Cell Death Discov
Pays: United States
ID NLM: 101665035
Informations de publication
Date de publication:
22 Apr 2021
22 Apr 2021
Historique:
received:
11
10
2020
accepted:
18
03
2021
revised:
21
02
2021
entrez:
23
4
2021
pubmed:
24
4
2021
medline:
24
4
2021
Statut:
epublish
Résumé
The 90K protein, also known as Mac-2 BP or LGALS3BP, can activate the immune response in part by increasing major histocompatibility (MHC) class I levels. In studies on a non-immune cell model, the rat FRTL-5 cell line, we observed that transforming growth factor (TGF)-β1, like γ-interferon (IFN), increased 90K levels, despite its immunosuppressive functions and the ability to decrease MHC class I. To explain this paradoxical result, we investigated the mechanisms involved in the TGF-β1 regulation of 90K expression with the aim to demonstrate that TGF-β1 utilizes different molecular pathways to regulate the two genes. We found that TGF-β1 was able to increase the binding of Upstream Stimulatory Factors, USF1 and USF2, to an E-box element, CANNTG, at -1926 to -1921 bp, upstream of the interferon response element (IRE) in the 90K promoter. Thyrotropin (TSH) suppressed constitutive and γ-IFN-induced 90K expression by decreasing USF binding to the E-box. TGF-β1 was able to overcome TSH suppression at the transcriptional level by increasing USF binding to the E-box. We suggest that the ability of TGF-β1 to increase 90K did not result in an increase in MHC class I because of a separate suppressive action of TGF-β1 directly on the MHC class I gene. We propose that the increased levels of 90K may play a role, rather than in immune response, in the context of the TGF-β1-induced changing of the cellular microenvironment that predisposes to cell motility and cancer progression. Consistently, analyzing the publicly available cancer patient data sets cBioPortal, we found that 90K expression directly correlated with TGF-β1 and USFs and that high levels of 90K were significantly associated with increased mortality in patients affected by different types of cancer.
Identifiants
pubmed: 33888686
doi: 10.1038/s41420-021-00469-1
pii: 10.1038/s41420-021-00469-1
pmc: PMC8062489
doi:
Types de publication
Journal Article
Langues
eng
Pagination
86Commentaires et corrections
Type : ErratumIn
Références
Morikawa, M., Derynck, R. & Miyazono, K. TGF-beta and the TGF-beta family: context-dependent roles in cell and tissue physiology. Cold Spring Harb. Perspect. Biol. 8, https://doi.org/10.1101/cshperspect.a021873 (2016).
Batlle, E. & Massague, J. Transforming growth factor-beta signaling in immunity and cancer. Immunity 50, 924–940 (2019).
pubmed: 30995507
pmcid: 7507121
doi: 10.1016/j.immuni.2019.03.024
Wrzesinski, S. H., Wan, Y. Y. & Flavell, R. A. Transforming growth factor-beta and the immune response: implications for anticancer therapy. Clin. Cancer Res. 13, 5262–5270 (2007).
pubmed: 17875754
doi: 10.1158/1078-0432.CCR-07-1157
Viel, S. et al. TGF-beta inhibits the activation and functions of NK cells by repressing the mTOR pathway. Sci. Signal 9, ra19 (2016).
pubmed: 26884601
doi: 10.1126/scisignal.aad1884
Chen, W. et al. Conversion of peripheral CD4+CD25- naive T cells to CD4+CD25+ regulatory T cells by TGF-beta induction of transcription factor Foxp3. J. Exp. Med. 198, 1875–1886 (2003).
pubmed: 14676299
pmcid: 2194145
doi: 10.1084/jem.20030152
Liu, Y. et al. A critical function for TGF-beta signaling in the development of natural CD4+CD25+Foxp3+ regulatory T cells. Nat. Immunol. 9, 632–640 (2008).
pubmed: 18438410
doi: 10.1038/ni.1607
Gorelik, L. & Flavell, R. A. Transforming growth factor-beta in T-cell biology. Nat. Rev. Immunol. 2, 46–53 (2002).
pubmed: 11905837
doi: 10.1038/nri704
Shull, M. M. et al. Targeted disruption of the mouse transforming growth factor-beta 1 gene results in multifocal inflammatory disease. Nature 359, 693–699 (1992).
pubmed: 1436033
pmcid: 3889166
doi: 10.1038/359693a0
Grassadonia, A. et al. 90K (Mac-2 BP) and galectins in tumor progression and metastasis. Glycoconj. J. 19, 551–556 (2002).
pubmed: 14758079
doi: 10.1023/B:GLYC.0000014085.00706.d4
Loimaranta, V., Hepojoki, J., Laaksoaho, O. & Pulliainen, A. T. Galectin-3-binding protein: a multitask glycoprotein with innate immunity functions in viral and bacterial infections. J. Leukoc. Biol. 104, 777–786 (2018).
pubmed: 29882603
doi: 10.1002/JLB.3VMR0118-036R
Ullrich, A. et al. The secreted tumor-associated antigen 90K is a potent immune stimulator. J. Biol. Chem. 269, 18401–18407 (1994).
pubmed: 8034587
doi: 10.1016/S0021-9258(17)32322-0
Natoli, C., Iacobelli, S. & Kohn, L. The immune stimulatory protein 90K increases major histocompatibility complex class I expression in a human breast cancer cell line. Biochem. Biophys. Res. Commun. 225, 617–620 (1996).
pubmed: 8753808
doi: 10.1006/bbrc.1996.1219
Kawashima, A. et al. Innate immune activation and thyroid autoimmunity. J. Clin. Endocrinol. Metab. 96, 3661–3671 (2011).
pubmed: 21956420
doi: 10.1210/jc.2011-1568
Grassadonia, A. et al. The 90K protein increases major histocompatibility complex class I expression and is regulated by hormones, gamma-interferon, and double-strand polynucleotides. Endocrinology 145, 4728–4736 (2004).
pubmed: 15231701
doi: 10.1210/en.2004-0506
Napolitano, G. et al. Transforming growth factor-beta1 down-regulation of major histocompatibility complex class I in thyrocytes: coordinate regulation of two separate elements by thyroid-specific as well as ubiquitous transcription factors. Mol. Endocrinol. 14, 486–505 (2000).
pubmed: 10770487
Pisarev, M. A., Thomasz, L. & Juvenal, G. J. Role of transforming growth factor beta in the regulation of thyroid function and growth. Thyroid 19, 881–892 (2009).
pubmed: 19645615
doi: 10.1089/thy.2007.0303
Carneiro, C., Alvarez, C. V., Zalvide, J., Vidal, A. & Dominguez, F. TGF-beta1 actions on FRTL-5 cells provide a model for the physiological regulation of thyroid growth. Oncogene 16, 1455–1465 (1998).
pubmed: 9525744
doi: 10.1038/sj.onc.1201662
Ambesi-Impiombato, F. S., Parks, L. A. & Coon, H. G. Culture of hormone-dependent functional epithelial cells from rat thyroids. Proc. Natl Acad. Sci. USA 77, 3455–3459 (1980).
pubmed: 6106191
pmcid: 349635
doi: 10.1073/pnas.77.6.3455
Veronese, A. et al. Mutated beta-catenin evades a microRNA-dependent regulatory loop. Proc. Natl Acad. Sci. USA 108, 4840–4845 (2011).
pubmed: 21383185
pmcid: 3064338
doi: 10.1073/pnas.1101734108
Grassadonia, A. et al. Upstream stimulatory factor regulates constitutive expression and hormonal suppression of the 90K (Mac-2BP) protein. Endocrinology 148, 3507–3517 (2007).
pubmed: 17446190
doi: 10.1210/en.2007-0024
Brakebusch, C. et al. Isolation and functional characterization of the human 90K promoter. Genomics 57, 268–278 (1999).
pubmed: 10198166
doi: 10.1006/geno.1999.5760
Giuliani, C. et al. Hormonal modulation of major histocompatibility complex class I gene expression involves an enhancer A-binding complex consisting of Fra-2 and the p50 subunit of NF-kappa B. J. Biol. Chem. 270, 11453–11462 (1995).
pubmed: 7744783
doi: 10.1074/jbc.270.19.11453
Muller, S. A. et al. Domain organization of Mac-2 binding protein and its oligomerization to linear and ring-like structures. J. Mol. Biol. 291, 801–813 (1999).
pubmed: 10452890
doi: 10.1006/jmbi.1999.2996
Howcroft, T. K. et al. Upstream stimulatory factor regulates major histocompatibility complex class I gene expression: the U2DeltaE4 splice variant abrogates E-box activity. Mol. Cell Biol. 19, 4788–4797 (1999).
pubmed: 10373528
pmcid: 84277
doi: 10.1128/MCB.19.7.4788
Riccio, A. et al. Transforming growth factor beta 1-responsive element: closely associated binding sites for USF and CCAAT-binding transcription factor-nuclear factor I in the type 1 plasminogen activator inhibitor gene. Mol. Cell Biol. 12, 1846–1855 (1992).
pubmed: 1549130
pmcid: 369628
Kutz, S. M. et al. TGF-beta 1-induced PAI-1 expression is E box/USF-dependent and requires EGFR signaling. Exp. Cell Res. 312, 1093–1105 (2006).
pubmed: 16457817
doi: 10.1016/j.yexcr.2005.12.027
Freytag, J. et al. PAI-1 mediates the TGF-beta1+EGF-induced ‘scatter’ response in transformed human keratinocytes. J. Invest. Dermatol 130, 2179–2190 (2010).
pubmed: 20428185
pmcid: 3774605
doi: 10.1038/jid.2010.106
Qi, L. et al. The basic helix-loop-helix/leucine zipper transcription factor USF2 integrates serum-induced PAI-1 expression and keratinocyte growth. J. Cell Biochem. 115, 1840–1847 (2014).
pubmed: 24905330
pmcid: 4134751
doi: 10.1002/jcb.24861
Shi, Y. & Massague, J. Mechanisms of TGF-beta signaling from cell membrane to the nucleus. Cell 113, 685–700 (2003).
pubmed: 12809600
doi: 10.1016/S0092-8674(03)00432-X
Macias, M. J., Martin-Malpartida, P. & Massague, J. Structural determinants of Smad function in TGF-beta signaling. Trends Biochem. Sci. 40, 296–308 (2015).
pubmed: 25935112
pmcid: 4485443
doi: 10.1016/j.tibs.2015.03.012
Zawel, L. et al. Human Smad3 and Smad4 are sequence-specific transcription activators. Mol. Cell 1, 611–617 (1998).
pubmed: 9660945
doi: 10.1016/S1097-2765(00)80061-1
Itoh, Y. et al. A comparative analysis of Smad-responsive motifs identifies multiple regulatory inputs for TGF-beta transcriptional activation. J. Biol. Chem. 294, 15466–15479 (2019).
pubmed: 31481467
pmcid: 6802517
doi: 10.1074/jbc.RA119.009877
Inman, G. J. & Hill, C. S. Stoichiometry of active smad-transcription factor complexes on DNA. J. Biol. Chem. 277, 51008–51016 (2002).
pubmed: 12374795
doi: 10.1074/jbc.M208532200
Zhou, S., Zawel, L., Lengauer, C., Kinzler, K. W. & Vogelstein, B. Characterization of human FAST-1, a TGF beta and activin signal transducer. Mol. Cell 2, 121–127 (1998).
pubmed: 9702198
doi: 10.1016/S1097-2765(00)80120-3
Derynck, R. & Zhang, Y. E. Smad-dependent and Smad-independent pathways in TGF-beta family signalling. Nature 425, 577–584 (2003).
pubmed: 14534577
doi: 10.1038/nature02006
Massague, J. TGFbeta signalling in context. Nat. Rev. Mol. Cell Biol. 13, 616–630 (2012).
pubmed: 22992590
pmcid: 4027049
doi: 10.1038/nrm3434
Sasaki, T., Brakebusch, C., Engel, J. & Timpl, R. Mac-2 binding protein is a cell-adhesive protein of the extracellular matrix which self-assembles into ring-like structures and binds beta1 integrins, collagens and fibronectin. EMBO J. 17, 1606–1613 (1998).
pubmed: 9501082
pmcid: 1170508
doi: 10.1093/emboj/17.6.1606
Ulmer, T. A. et al. The tumor-associated antigen 90K/Mac-2-binding protein secreted by human colon carcinoma cells enhances extracellular levels of promatrilysin and is a novel substrate of matrix metalloproteinases-2, −7 (matrilysin) and −9: Implications of proteolytic clea. Biochim. Biophys. Acta 1800, 336–343 (2010).
pubmed: 19665518
doi: 10.1016/j.bbagen.2009.07.030
Iacobelli, S. et al. Prognostic value of a novel circulating serum 90K antigen in breast cancer. Br. J. Cancer 69, 172–176 (1994).
pubmed: 8286203
pmcid: 1968766
doi: 10.1038/bjc.1994.29
Marchetti, A. et al. Expression of 90K (Mac-2 BP) correlates with distant metastasis and predicts survival in stage I non-small cell lung cancer patients. Cancer Res. 62, 2535–2539 (2002).
pubmed: 11980646
Tinari, N. et al. High expression of 90K (Mac-2 BP) is associated with poor survival in node-negative breast cancer patients not receiving adjuvant systemic therapies. Int J. Cancer 124, 333–338 (2009).
pubmed: 18942707
doi: 10.1002/ijc.23970
Elliott, R. L. & Blobe, G. C. Role of transforming growth factor Beta in human cancer. J. Clin. Oncol. 23, 2078–2093 (2005).
pubmed: 15774796
doi: 10.1200/JCO.2005.02.047
Narai, S. et al. Significance of transforming growth factor beta1 as a new tumor marker for colorectal cancer. Int J. Cancer 97, 508–511 (2002).
pubmed: 11802214
doi: 10.1002/ijc.1631
Shariat, S. F. et al. Tissue expression of transforming growth factor-beta1 and its receptors: correlation with pathologic features and biochemical progression in patients undergoing radical prostatectomy. Urology 63, 1191–1197 (2004).
pubmed: 15183988
doi: 10.1016/j.urology.2003.12.015
Cantelli, G., Crosas-Molist, E., Georgouli, M. & Sanz-Moreno, V. TGFBeta-induced transcription in cancer. Semin. Cancer Biol. 42, 60–69 (2017).
pubmed: 27586372
pmcid: 6137079
doi: 10.1016/j.semcancer.2016.08.009
Ahmadi, A., Najafi, M., Farhood, B. & Mortezaee, K. Transforming growth factor-beta signaling: Tumorigenesis and targeting for cancer therapy. J. Cell Physiol. 234, 12173–12187 (2019).
pubmed: 30537043
doi: 10.1002/jcp.27955
Bierie, B. & Moses, H. L. Tumour microenvironment: TGFbeta: the molecular Jekyll and Hyde of cancer. Nat. Rev. Cancer 6, 506–520 (2006).
pubmed: 16794634
doi: 10.1038/nrc1926
Massague, J. TGFbeta in cancer. Cell 134, 215–230 (2008).
pubmed: 18662538
pmcid: 3512574
doi: 10.1016/j.cell.2008.07.001
Xu, J., Lamouille, S. & Derynck, R. TGF-beta-induced epithelial to mesenchymal transition. Cell Res. 19, 156–172 (2009).
pubmed: 19153598
doi: 10.1038/cr.2009.5
McCormack, N. & O’Dea, S. Regulation of epithelial to mesenchymal transition by bone morphogenetic proteins. Cell Signal 25, 2856–2862 (2013).
pubmed: 24044921
doi: 10.1016/j.cellsig.2013.09.012
Hirahata, M. et al. PAI-1, a target gene of miR-143, regulates invasion and metastasis by upregulating MMP-13 expression of human osteosarcoma. Cancer Med. 5, 892–902 (2016).
pubmed: 26817521
pmcid: 4864819
doi: 10.1002/cam4.651
Gomes-Giacoia, E., Miyake, M., Goodison, S. & Rosser, C. J. Targeting plasminogen activator inhibitor-1 inhibits angiogenesis and tumor growth in a human cancer xenograft model. Mol. Cancer Ther. 12, 2697–2708 (2013).
pubmed: 24072883
pmcid: 4317369
doi: 10.1158/1535-7163.MCT-13-0500
Palmirotta, R. et al. Prognostic value of pre-surgical plasma PAI-1 (plasminogen activator inhibitor-1) levels in breast cancer. Thromb. Res. 124, 403–408 (2009).
pubmed: 19351570
doi: 10.1016/j.thromres.2009.02.014
Halamkova, J. et al. Clinical relevance of uPA, uPAR, PAI 1 and PAI 2 tissue expression and plasma PAI 1 level in colorectal carcinoma patients. Hepatogastroenterology 58, 1918–1925 (2011).
pubmed: 22234062
Ferroni, P. et al. Plasma plasminogen activator inhibitor-1 (PAI-1) levels in breast cancer - relationship with clinical outcome. Anticancer Res. 34, 1153–1161 (2014).
pubmed: 24596353
Chen, H. et al. Silencing of plasminogen activator inhibitor-1 suppresses colorectal cancer progression and liver metastasis. Surgery 158, 1704–1713 (2015).
pubmed: 26275833
doi: 10.1016/j.surg.2015.04.053
Fredstorp-Lidebring, M. et al. Urokinase plasminogen activator and its inhibitor, PAI-1, in association with progression-free survival in early stage endometrial cancer. Eur. J. Cancer 37, 2339–2348 (2001).
pubmed: 11720826
doi: 10.1016/S0959-8049(01)00306-9
Omori, K. et al. Inhibition of plasminogen activator inhibitor-1 attenuates transforming growth factor-beta-dependent epithelial mesenchymal transition and differentiation of fibroblasts to myofibroblasts. PLoS ONE 11, e0148969 (2016).
pubmed: 26859294
pmcid: 4747467
doi: 10.1371/journal.pone.0148969
Thiery, J. P. Epithelial-mesenchymal transitions in tumour progression. Nat. Rev. Cancer 2, 442–454 (2002).
pubmed: 12189386
doi: 10.1038/nrc822
Chen, Y. et al. Transforming growth factor beta signaling pathway: a promising therapeutic target for cancer. J. Cell Physiol. 235, 1903–1914 (2020).
pubmed: 31332789
doi: 10.1002/jcp.29108
Li, S. et al. Plasminogen activator inhibitor-1 in cancer research. Biomed. Pharmacother. 105, 83–94 (2018).
pubmed: 29852393
doi: 10.1016/j.biopha.2018.05.119